- Achieve Life Sciences Inc ACHV has priced its underwritten public offering of 2.9 million at $7 per share, representing a discount of 19% from the last close price of $8.61.
- Underwriters have a 30-day option to purchase up to an additional 428 thousand shares.
- The offering is expected to close by May 27.
- The gross proceeds of approximately $20 million will fund ongoing cytisinicline development, other clinical R&D, working capital, and general corporate purposes.
- Price Action: ACHV shares are down 11.7% at $7.63 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
